Cover Image
市場調查報告書

癌症增生抑制劑的市場及臨床實驗平台分析

Cancer Growth Inhibitors Market & Clinical Pipeline Analysis

出版商 KuicK Research 商品編碼 328387
出版日期 內容資訊 英文 1000 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症增生抑制劑的市場及臨床實驗平台分析 Cancer Growth Inhibitors Market & Clinical Pipeline Analysis
出版日期: 2015年04月01日 內容資訊: 英文 1000 Pages
簡介

全球製藥產業到目前為止,經過多年的研究和大金額的投資終於開發出了許多癌症治療藥。現在,每年也有許多的癌症治療藥重新上市。大型製藥企業投資大金額在研究開發 (R&D) 活動上進行臨床實驗平台的擴充,癌症抑制劑的市場競爭今後應將更為活躍。

本報告提供全球的癌症增生抑制劑臨床實驗進展相關分析、技術上的特性和主要的推動及阻礙市場要素、主要藥物 (癌症蛋白酪氨酸激酶、HDAC抑制劑、MTOR蛋白質抑制劑、PI3k抑制劑、蛋白酶體抑制劑) 的目前臨床實驗進展、主要企業簡介等資訊彙整,為您概述為以下內容。

第1章 簡介:癌症增生抑制劑

第2章 癌症增生抑制劑的分類

第3章 癌症增生抑制劑的機制

第4章 全球癌症增生抑制劑市場概要

  • 目前市場方案
  • 癌症增生抑制劑的臨床實驗平台概要

第5章 全球癌症增生抑制劑市場動態

  • 有利的市場參數
  • 企業化時的課題

第6章 全球癌症增生抑制劑市場未來展望

第7章 癌症蛋白酪氨酸激酶臨床分析:各企業、各適應症、各Phase

  • 不明
  • 研究階段
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段
  • 登記前
  • 登記完畢

第8章 已上市癌症蛋白酪氨酸激酶臨床分析

第9章 HDAC抑制劑臨床分析:各企業、各適應症、各Phase

  • 研究階段
  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段
  • 登記後

第10章 已上市HDAC抑制劑臨床分析:各企業、各適應症

第11章 MTOR蛋白質抑制劑臨床分析:各企業、各適應症、各Phase

  • 研究階段
  • 前臨床
  • 臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段
  • 登記前
  • 登記後

第12章 已上市MTOR蛋白質抑制劑臨床分析:各企業、各適應症

第13章 PI3k抑制劑臨床分析:各企業、各適應症、各Phase

  • 研究階段
  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第二/三階段
  • 第三階段

第14章 已上市PI3k抑制劑臨床分析:各企業、各適應症

第15章 蛋白酶體抑制劑臨床分析:各企業、各適應症、各Phase

  • 研究階段
  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段

第16章 已上市蛋白酶體抑制劑臨床分析:各企業、各適應症

第17章 競爭情形

  • Advaxis
  • Amgen
  • AstraZeneca
  • Bristol Mayer Squibb
  • Celldex Therapeutics
  • Eli Lily
  • GalaxoSmithKline
  • Genetech
  • ImmunoCellular Therapeutics
  • ImmunoGen
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Teva

圖表一覽

目錄

Pharmaceutical industry consists of various products for cancer treatment and several years of research along with significant investments have helped in developing many innovative products. Every year, new cancer therapeutic belonging to different drug category is introduced across the globe. Cancer growth inhibitors are recent additions as compared to conventional therapeutics which have modest pharmacological potential. Pharmaceutical companies have been able to introduce newer cancer growth inhibitors for different cancer categories to overcome therapeutic and commercialization barriers. Due to higher investments in research and development, their clinical pipeline is becoming stronger and novel cancer growth inhibitors for different cancers are entering in global market. Their rate of market introduction is expected to increase in coming years due to technological advancements and increased funding. Consequently, market introduction of these cancer growth inhibitors is expected to offer severe competition to existing cancer therapeutics in global market.

Cancer growth inhibitors market shows overlapping boundaries due to which it becomes difficult to demarcate different categories. For instance, a tyrosine kinase may be a small molecules or a large molecule because they have same inhibitory molecule. On the other hand, they may inhibit cellular processes and belong to different molecular classes. Despite these differences, cancer growth inhibitors occupy large market shares and targeted therapeutics seems to be the major contenders. They have high safety and efficacy profiles along with minimized side effects due to which large number of patients are including them as a part of their regular therapeutic regime. In coming years, they are expected to become main focus of pharmaceutical companies because conventional cancer therapies like chemotherapy have proved to have modest efficacy. In future, their therapeutic efficacy is expected to increase and many innovative products are at different phases of clinical development due to which their global market is expected to witness steady growth.

Clinical pipeline of cancer growth inhibitors is increasing due to innovations and potential competition from newly developed cancer drugs. Pharmaceutical companies are focusing on approaches like utilization of next generation sequencing and computerized simulation to prevent undue wastage of time and resources. Relapse is another biggest issues associated with conventional cancer therapeutics which could be prevented with the help of cancer growth inhibitors. Innovative cancer growth inhibitors are expected to increase average survival time and decrease mortality rates. These factors are expected to increase the demand for cancer growth inhibitors but still lots of modalities have to be streamlined in order to offer sustainable competition to newly coming cancer therapeutics belonging to other drug categories. One of the major steps in order to overcome these shortcomings could be the utilization of high end technology.

Cancer Growth Inhibitors Covered in Report:

  • Cancer Tyrosine Kinase
  • Proteasome Inhibitors
  • MTOR Protein Inhibitors
  • Histone Deacetylase Inhibitors (HDAC inhibitors)
  • PI3k

"Cancer Growth Inhibitors Market & Clinical Pipeline Analysis" Report Highlight:

  • Introduction & Classification of Cancer Growth Inhibitors
  • Cancer Growth Inhibitors Clinical Pipeline by Company, Indication & Phase
  • Cancer Growth Inhibitors Clinical Pipeline: 629 Drugs
  • Markets Cancer Growth Inhibitors: 48 Drugs
  • Tyrosine Kinase Dominates Cancer Growth Inhibitors Pipeline: 394 Drugs
  • HDAC Inhibitors Clinical Pipeline: 65 Drugs
  • MTOR Protein Inhibitors Clinical Pipeline: 62 Drugs
  • PI3k Clinical Pipeline: 89 Drugs
  • Proteasome Inhibitors Clinical Pipeline: 19 Drugs
  • Global Cancer Growth Inhibitors Market Future Prospects

Table of Contents

1. Introduction to Cancer Growth Inhibitors

2. Classification of Cancer Growth Inhibitors

3. Cancer Growth Inhibitors Mechanism

4. Global Cancer Growth Inhibitors Market Overview

  • 4.1 Current Market Scenario
  • 4.2 Cancer Growth Inhibitors Clinical Pipeline Overview

5. Global Cancer Growth Inhibitors Market Dynamics

  • 5.1 Favorable Market Parameters
  • 5.2 Commercialization Challenges

6. Global Cancer Growth Inhibitors Market Future Prospects

7. Cancer Tyrosine Kinase Clinical Insight by Company, Indication & Phase

  • 7.1 Unknown
  • 7.2 Research
  • 7.3 Preclinical
  • 7.4 Clinical
  • 7.5 Phase-I
  • 7.6 Phase-I/II
  • 7.7 Phase-II
  • 7.8 Phase-II/III
  • 7.9 Phase-III
  • 7.10 Preregistration
  • 7.11 Registered

8. Marketed Cancer Tyrosine Kinase Clinical Insight

9. HDAC Inhibitors Clinical Insight by Company, Indication & Phase

  • 9.1 Research
  • 9.2 Preclinical
  • 9.3 Phase-I
  • 9.4 Phase-I/II
  • 9.5 Phase-II
  • 9.6 Phase-III
  • 9.7 Registered

10. Marketed HDAC Inhibitors Clinical Insight by Company & Indication

11. MTOR Protein Inhibitors Clinical Insight by Company, Indication & Phase

  • 11.1 Research
  • 11.2 Preclinical
  • 11.3 Clinical
  • 11.4 Phase-I
  • 11.5 Phase-I/II
  • 11.6 Phase-II
  • 11.7 Phase-III
  • 11.8 Preregistration
  • 11.9 Registered

12. Marketed MTOR Protein Inhibitors Clinical Insight by Company & Indication

13. PI3K Inhibitors Clinical Insight by Company, Indication & Phase

  • 13.1 Research
  • 13.2 Preclinical
  • 13.3 Phase-I
  • 13.4 Phase-I/II
  • 13.5 Phase-II
  • 13.6 Phase-II/III
  • 13.7 Phase-III

14. Marketed PI3K Inhibitors Clinical Insight by Company & Indication

15. Proteasome Inhibitors Clinical Insight by Company, Indication & Phase

  • 15.1 Research
  • 15.2 Preclinical
  • 15.3 Phase-I
  • 15.4 Phase-I/II
  • 15.5 Phase-II
  • 15.6 Phase-III

16. Marketed Proteasome Inhibitors Clinical Insight by Company & Indication

17. Competitive Landscape

  • 17.1 Advaxis
  • 17.2 Amgen
  • 17.3 AstraZeneca
  • 17.4 Bristol Mayer Squibb
  • 17.5 Celldex Therapeutics
  • 17.6 Eli Lily
  • 17.7 GalaxoSmithKline
  • 17.8 Genetech
  • 17.9 ImmunoCellular Therapeutics
  • 17.10 ImmunoGen
  • 17.11 Merck
  • 17.12 Novartis
  • 17.13 Pfizer
  • 17.14 Roche
  • 17.15 Sanofi
  • 17.16 Teva

List of Figures

  • Figure 1-1: Benefits of Cancer Growth Inhibitors
  • Figure 1-2: Functions of Cancer Growth Inhibitors
  • Figure 1-3: Improvement Required for Cancer Growth Inhibitor
  • Figure 2-1: Cancer Growth Inhibitors Classification
  • Figure 2-2: Different Cancer Growth Inhibitors on the Basis of their Targets
  • Figure 3-1: Generalized Working of Cancer Growth Inhibitors
  • Figure 3-2: Mechanism of Bortezomib
  • Figure 3-3: Mechanism of Vismodegib
  • Figure 3-4: Mechanism of Everolimus
  • Figure 3-5: Mechanism of Bevacizumab
  • Figure 3-6: Mechanism of Imatinib
  • Figure 4-1: Cancer Growth Inhibitors Pipeline by Phase(%), 2015
  • Figure 4-2: Cancer Growth Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-3: Cancer Tyrosine Kinase Disease Pipeline by Phase (%), 2015
  • Figure 4-4: Cancer Tyrosine Kinase Disease Pipeline by Phase (Numbers), 2015
  • Figure 4-5: HDAC Pipeline by Phase (%), 2015
  • Figure 4-6: HDAC Pipeline by Phase (Number), 2015
  • Figure 4-7: Discontinued HDAC Pipeline by Phase (%), 2015
  • Figure 4-8: Discontinued HDAC Pipeline by Phase (Number), 2015
  • Figure 4-9: MTOR Protein Inhibitors Pipeline by Phase (%), 2015
  • Figure 4-10: MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-11: Discontinued MTOR Protein Inhibitors Pipeline by Phase (%), 2015
  • Figure 4-12: Discontinued MTOR Protein Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-13: PI3K Pipeline by Phase (%), 2015
  • Figure 4-14: PI3K Pipeline by Phase (Number), 2015
  • Figure 4-15: Discontinued PI3K Pipeline by Phase (%), 2015
  • Figure 4-16: Discontinued PI3K Pipeline by Phase (Number), 2015
  • Figure 4-17: Proteasome Inhibitors Pipeline by Phase (%), 2015
  • Figure 4-18: Proteasome Inhibitors Pipeline by Phase (Number), 2015
  • Figure 4-19: No Development Reported Proteasome Inhibitors Pipeline by Phase (%), 2015
  • Figure 4-20: No Development Reported Proteasome Inhibitors Pipeline by Phase (Number), 2015
  • Figure 5-1: Global Cancer Growth Inhibitors Market Favorable Parameters
  • Figure 5-2: Cancer Growth Inhibitors Market Commercialization Challenges
  • Figure 17-1: Advaxis Clinical Pipeline
  • Figure 17-2: Celldex Therapeutics Clinical Pipeline
  • Figure 17-3: ImmunoCellular Therapeutics Clinical Pipeline
  • Figure 17-4: ImmunoGen Clinical Pipeline
Back to Top